- Home
- CYCC vs SLXN Comparison
CYCC vs SLXN Comparison
Compare CYCC & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- SLXN
- Stock Information
- Founded
- CYCC 1992
- SLXN 2008
- Country
- CYCC United States
- SLXN Israel
- Employees
- CYCC N/A
- SLXN N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- SLXN
- Sector
- CYCC Health Care
- SLXN
- Exchange
- CYCC Nasdaq
- SLXN NYSE
- Market Cap
- CYCC 3.6M
- SLXN 4.3M
- IPO Year
- CYCC N/A
- SLXN N/A
- Fundamental
- Price
- CYCC $0.34
- SLXN $0.84
- Analyst Decision
- CYCC Strong Buy
- SLXN Strong Buy
- Analyst Count
- CYCC 1
- SLXN 1
- Target Price
- CYCC $11.00
- SLXN $9.00
- AVG Volume (30 Days)
- CYCC 404.4K
- SLXN 31.1M
- Earning Date
- CYCC 03-18-2025
- SLXN 03-04-2025
- Dividend Yield
- CYCC N/A
- SLXN N/A
- EPS Growth
- CYCC N/A
- SLXN N/A
- EPS
- CYCC N/A
- SLXN N/A
- Revenue
- CYCC $74,000.00
- SLXN N/A
- Revenue This Year
- CYCC N/A
- SLXN N/A
- Revenue Next Year
- CYCC $88.68
- SLXN N/A
- P/E Ratio
- CYCC N/A
- SLXN N/A
- Revenue Growth
- CYCC N/A
- SLXN N/A
- 52 Week Low
- CYCC $0.30
- SLXN $0.21
- 52 Week High
- CYCC $4.00
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- CYCC 46.57
- SLXN N/A
- Support Level
- CYCC $0.32
- SLXN N/A
- Resistance Level
- CYCC $0.38
- SLXN N/A
- Average True Range (ATR)
- CYCC 0.02
- SLXN 0.00
- MACD
- CYCC 0.00
- SLXN 0.00
- Stochastic Oscillator
- CYCC 50.00
- SLXN 0.00
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.